Triple-target treatment versus low-frequency electrostimulation for anal incontinence: a randomized, controlled trial

Area of Science:

• Coloproctology
• Pelvic floor rehabilitation

Background:

• Nonsurgical treatment for anal incontinence often involves biofeedback and electrical stimulation.
• Triple-target treatment (3T), a combination of amplitude-modulated medium-frequency stimulation and electromyographic biofeedback (EMG-BF), has shown promise.
• This study compares 3T to standard low-frequency stimulation (LFS).

Purpose of the Study:

• To compare the efficacy of 3T versus LFS in treating anal incontinence.
• To evaluate the impact of these treatments on continence and quality of life.

Main Methods:

• A multicenter randomized trial with blinded observer involving 80 patients with anal incontinence (Grade I or higher).
• Patients were randomized to receive either 3T or LFS for two 20-minute sessions daily over 6 months.
• Primary endpoint: Cleveland Clinic Score (CCS); Secondary endpoints: continence recovery and quality of life (QoL).

Main Results:

• The 3T group showed a significantly lower mean CCS (3.1 ± 4.2) compared to the LFS group (9.6 ± 3.9) after 6 months.
• 54% of patients in the 3T group regained continence, versus 0% in the LFS group (p<0.001).
• All QoL dimensions were higher in the 3T group; no major adverse effects were reported.

Conclusions:

• Triple-target treatment (3T) is superior to low-frequency stimulation (LFS) for anal incontinence.
• The combination of biofeedback and medium-frequency stimulation in 3T appears effective.
• LFS, as applied in this trial, demonstrated no significant benefit.